Chan Mitchell Sells 3,166 Shares of Avalo Therapeutics Common Stock

Chan Mitchell, a director at Avalo Therapeutics, Inc., reported a transaction on March 28, 2026. Mitchell acquired 3,166 shares of common stock through the conversion of 3,166 Restricted Stock Units (RSUs). The RSUs were granted on August 13, 2024, with vesting scheduled in three tranches on March 28, 2025, March 28, 2026, and March 28, 2027. This specific transaction reflects the vesting of the second tranche. Following this transaction, Mitchell directly owns 6,333 shares of common stock. The conversion of RSUs into common stock is based on a one-for-one exchange rate.